Sorafenib Drug Drug Interaction Study in Healthy Male Subjects
Sorafenib Drug Drug Interaction Study in Healthy Male Subjects
To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and
 elimination of sorafenib and safety in healthy male subjects
Inclusion Criteria:

 -  Healthy male subjects between the ages of 18 (inclusive) and 45 years (inclusive) at
 the first screening visit.

 -  Body mass index (BMI) between 18.5 (inclusive) to 30.0 kg / m² (inclusive) with body
 weight ≥ 65kg.

 -  Normal thyroid function indicated by thyroid examination to include total and free T3
 (Triiodothyronine) , T4 (total and free Thyroxine, levothyroxine), TSH (Thyroid
 stimulating hormone), anti-TSH-receptor (anti-TSHR) antibody, anti-thyroperoxidase
 (anti-TPO) antibody, anti-thyroglobulin antibody (anti-ATA) as well as thyroid
 ultrasound.

 Exclusion Criteria:

 -  History of clinically significant metabolic, renal, hepatic, or central nervous system
 disorder such as seizure, psychosis and sleep disorders.

 -  History of cardiovascular diseases including arrhythmia, hypertension, ischemia, etc.

 -  Known or suspected cardiovascular disease including potential risk of atrioventricular
 (AV) block, arrhythmia, etc. with or without a formal cardiologist consultation.

 -  Subjects who had received iodine containing contrast medium within 2 months before
 first study drug administration.

 -  Use of systemic or topical medicines or substances which might affect the study
 drug(s) must be avoided